HLS Therapeutics Inc.
Other OTCTotal Valuation
HLS Therapeutics Inc. carries a market capitalization of 82.57M, placing it among publicly traded companies globally. Its enterprise value stands at 121.98M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 82.57M |
| Enterprise Value | 121.98M |
Share Statistics
HLS Therapeutics Inc. currently has 31.27M shares outstanding.
| Shares Outstanding | 31.27M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 1.73, and the price-to-book ratio stands at 1.70.
| PE Ratio | N/A |
| PS Ratio | 1.73 |
| PB Ratio | 1.70 |
| P/TBV Ratio | -2.33 |
| P/FCF Ratio | 5.06 |
| P/OCF Ratio | 5.34 |
Enterprise Valuation
On an enterprise value basis, HLS Therapeutics Inc. trades at an EV/EBITDA multiple of 6.96 and an EV/FCF ratio of 5.12.
| EV / Sales | 2.17 |
| EV / EBITDA | 6.96 |
| EV / EBIT | N/A |
| EV / FCF | 5.12 |
Financial Position
HLS Therapeutics Inc. maintains a current ratio of 1.05, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 75.86, indicating elevated leverage, while an interest coverage ratio of 3.58 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.05 |
| Quick Ratio | 0.76 |
| Debt / Equity | 75.86 |
| Debt / EBITDA | 2.39 |
| Interest Coverage | 3.58 |
Financial Efficiency
| Return on Equity (ROE) | -14.07 |
| Return on Assets (ROA) | -6.17 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 1.65 |
Taxes
| Income Tax | -649,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
HLS Therapeutics Inc.'s stock has declined approximately -30.52632% over the past 52 weeks. The 50-day moving average sits at 2.91, while the 200-day moving average is 3.21.
| Beta (5Y) | N/A |
| 52-Week Price Change | -30.52632% |
| 50-Day Moving Average | 2.91 |
| 200-Day Moving Average | 3.21 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, HLS Therapeutics Inc. generated 56.24M in revenue and converted that into -8.57M in net income, yielding earnings per share of -0.26. EBITDA reached 17.53M, while operating income came in at -4.51M.
| Revenue | 56.24M |
| Gross Profit | 45.53M |
| Operating Income | -4.51M |
| Pretax Income | -9.22M |
| Net Income | -8.57M |
| EBITDA | 17.53M |
| EBIT | -4.51M |
| Earnings Per Share (EPS) | -0.26 |
Balance Sheet
HLS Therapeutics Inc. holds 13.73M in cash and equivalents against 41.90M in total debt, resulting in a net debt position of 27.45M. Total book value stands at 55.24M, with working capital of 1.42M providing operational flexibility.
| Cash & Cash Equivalents | 13.73M |
| Total Debt | 41.90M |
| Net Debt | 27.45M |
| Equity (Book Value) | 55.24M |
| Book Value Per Share | 1.77 |
| Working Capital | 1.42M |
Cash Flow
HLS Therapeutics Inc. produced 18.25M in operating cash flow over the past twelve months. After subtracting -1.04M in capital expenditures, free cash flow totaled 17.21M - equivalent to 0.53 per share.
| Operating Cash Flow | 18.25M |
| Capital Expenditures | -1.04M |
| Free Cash Flow | 17.21M |
| FCF Per Share | 0.53 |
Margins
HLS Therapeutics Inc. operates with a gross margin of 80.95, reflecting its pricing power and cost economics. The operating margin of -8.02 and net profit margin of -15.24 provide insight into operational efficiency.
| Gross Margin | 80.95 |
| Operating Margin | -8.02 |
| Pretax Margin | -16.39 |
| Profit Margin | -15.24 |
| EBITDA Margin | 31.16 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | 16.31 |
| FCF Yield | 19.77 |
Scores
HLS Therapeutics Inc. posts an Altman Z-Score of -6.70, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -6.70 |